Mohamed F. Doheim, MD, PhD, FRCP, Neuroscientist

180+

Peer-reviewed
publications

5,000+

Citations
(Google Scholar)

20+

h-index

About

At the intersection of AI & stroke care

I integrate causal inference, machine learning, and clinical-trial design to move beyond one-size-fits-all treatment toward individualized therapeutic strategies in acute ischemic stroke.

As Founding Co-Director of NeuroPrecision Lab, CEO of the Pitt-licensed startup HORUS NeuroTechnologies, and Primary Manager of the DUSK Trial, I bridge computational innovation with direct patient care, from counterfactual treatment models in Annals of Neurology to an AI triage platform spanning a 60-spoke hospital network.

Full Biography Pitt Profile

Key Appointments

2026-PRESENT

Clinical Research Assistant Professor of Neurology

UPMC Stroke Institute, University of Pittsburgh

2026-PRESENT

Chief Executive Officer, HORUS NeuroTechnologies LLC

Pitt-licensed startup, clinical decision support

2025-PRESENT

Founding Co-Director & PI, NeuroPrecision Lab

UPMC Stroke Institute, University of Pittsburgh

2025-PRESENT

Primary Manager & Co-Investigator, DUSK Trial

Multicenter RCT, DMVO thrombectomy

2024-2026

PhD, Department of Neurology

Maastricht University, The Netherlands

Research & Innovation

Areas of impact

Precision Medicine

Causal ML and counterfactual (CATE) estimation for individualized EVT decisions in distal, medium-vessel, and posterior-circulation stroke.

PMID 41603297

AI-Enabled Stroke Systems

AI triage across a 60-spoke network improving workflow and transfer efficiency; the LUCID clinical decision-support platform.

Pitt Invention

Clinical Trial Leadership

Primary Manager & Co-Investigator of the multicenter DUSK Trial for DMVO thrombectomy; roles in BOLT and tenecteplase time-window studies.

DUSK Trial

Innovation & Translation

CEO of HORUS NeuroTechnologies (Pitt-licensed); provisional patents for an intracranial stent and an AI-powered stroke decision-support platform.

Evidence Synthesis

Landmark meta-analyses in The Lancet (VERITAS), Annals of Neurology (ATLAS-ER), and Neurology.

Global Health Impact

Global Burden of Disease collaborator: stroke and neurological burden in Lancet Neurology, JAMA Neurology, and Lancet Global Health.

All Research & Publications

Selected Publications

Recent high-impact work

Between-Study Heterogeneity in Extended-Window IV Thrombolysis for Acute Ischemic Stroke: Meta-Analysis of 18 RCTs

Doheim MF, Al-Qudah AM, Singh R, et al.

Neurology. 2026;107(3):e218331

First Author PMID 42475651

Impact of an AI-Driven Triage System on Workflow and Transfer Efficiency: 4,548 Admissions Across Four Hubs and Sixty Spokes

Doheim MF, Starr M, Bhatt NR, et al.

J Neurol Neurosurg Psychiatry. 2026;97(7):620-629

First Author PMID 41895841

Individualized Treatment in DMVO Stroke Using a Validated Explainable Counterfactual Treatment-Estimation Model

Doheim MF, Mohammaden MH, Abdelhamid H, et al.

Annals of Neurology. 2026;99(5):1198-1209

First Author PMID 41603297

ATLAS-ER: Adjunctive Thrombolytics After Successful Endovascular Reperfusion, a Meta-Analysis of RCTs

Doheim MF, Mohammaden MH, Jumah A, et al.

Annals of Neurology. 2025;98(6):1299-1314

First Author PMID 40799167

Direct Endovascular vs Bridging Therapy in M2-Segment Occlusion: MR CLEAN Registry (IPTW)

Doheim MF, Knapen RRMM, Staals J, et al.

Stroke. 2025;56(10):2866-2878

First Author PMID 40878683

Meta-Analysis of RCTs on IV Thrombolysis in Minor Acute Ischemic Stroke

Doheim MF, Nguyen TN, Xiong Y, et al.

Neurology. 2025;105(3):e213863

First Author PMID 40674672

View All Publications

Connect

Let's collaborate

Open to collaborations in precision stroke medicine, AI in clinical trials, and neurovascular innovation.

Get in Touch NeuroPrecision Lab